Skip to main content

Table. 2 HRs and 95% CIs of cancer prognosis and progression associated with TSP-1 expression in included studies

From: Role of TSP-1 as prognostic marker in various cancers: a systematic review and meta-analysis

First author, Publication year

Cut-off value

Number of cases

OS

DFS/RFS

PFS/MFS

High expression

low expression

Total

HR (95% CI)

P Value

HR (95% CI)

P Value

HR (95% CI)

P Value

Nakamura et al., 2019

10% of the cells were positive

86

120

206

N/A

N/A

N/A

N/A

1.11 (0.56–2.19)

0.774

Tzeng et al., 2016

value =40

76

107

183

N/A

N/A

N/A

N/A

0.61 (0.38–0.99)

< 0.001

Rouanne et al., 2016

Median

N/A

N/A

171

0.15 (0.03–0.89)

0.04

0.39 (0.10–1.45)

0.23

N/A

N/A

Teraoku et al., 2016

score = 3

35

59

94

2.61 (1.00–8.16)

< 0.01

0.63 (0.38–1.06)

0.06

N/A

N/A

Campone et al., 2015

positive

19

14

33

0.86 (0.08–8.85)

0.0364

N/A

N/A

N/A

N/A

Eto et al., 2015

10% of the cells were positive

17

48

65

0.53 (0.24–1.18)

< 0.05

N/A

N/A

N/A

N/A

Yao et al., 2014

Median

N/A

N/A

68

1.52 (0.91–3.14)

0.088

1.62 (0.91–3.76)

0.112

N/A

N/A

Sharma et al., 2013

Median

N/A

N/A

67

0.982 (0.541–1.784)

0.953

N/A

N/A

N/A

N/A

Pectasides et al., 2012

Median

60

60

120

1.84 (1.11–3.05)

0.018

N/A

N/A

1.73 (1.11–2.69)

0.016

Nakao et al., 2011

30% of the cells were positive

17

48

65

0.54 (0.26–1.14)

< 0.01

N/A

N/A

N/A

N/A

Zhou et al., 2009

10 percentile

72

8

80

0.41 (0.07–2.38)

0.042

N/A

N/A

N/A

N/A

Randall et al., 2009

score = 3

112

54

166

1.44 (0.70–2.75)

0.32

N/A

N/A

1.30 (0.67–2.54)

0.44

Yang et al., 2009

moderate staining

25

45

70

N/A

N/A

0.77 (0.18–3.42)

0.012

N/A

N/A

Secord et al., 2007

Median

32

35

67

1.93 (1.12–3.32)

0.018

N/A

N/A

2.19 (1.29–3.71)

0.004

Wada et al., 2006

score = 2

9

51

60

N/A

N/A

2.85 (1.05–7.72)

0.689

N/A

N/A

Sutton et al., 2005

Median

45

137

182

1.82 (1.0–3.1)

0.01

N/A

N/A

N/A

N/A

Fontana et al., 2005

positive

54

23

77

N/A

N/A

N/A

N/A

2.25 (0.81–6.27)

0.07

Poon et al., 2004

0.75

15

45

60

2.49 (0.63–9.86)

0.014

N/A

N/A

N/A

N/A

Aishima et al., 2002

50% of the cells were positive

34

33

67

1.39 (0.70–2.78)

0.08

N/A

N/A

N/A

N/A

Maeda et al., 2001

positive

89

61

150

N/A

N/A

2.37 (1.41–3.83)

0.03

N/A

N/A

Straume et al., 2001

moderate staining

77

104

181

2.07 (1.27–3.40)

0.0001

N/A

N/A

N/A

N/A

Kodama et al., 2001

positive

31

23

54

N/A

N/A

3.16 (1.25–7.98)

0.015

N/A

N/A

You et al., 2000

5% of the cells were positive

29

10

39

1.49 (0.48–4.58)

0.0163

N/A

N/A

N/A

N/A

Yao et al., 2000

moderate staining

22

32

54

0.81 (0.14–4.58)

0.045

N/A

N/A

N/A

N/A

  1. OS, overall survival; DFS, disease-free survival; MFS, metastasis-free survival; RFS, recurrence-free survival; PFS, progression-free survival; HR, hazard ratio; CI, confidence interval; N/A, not available
Back to article page

BMC Medical Genetics

ISSN: 1471-2350

Contact us